Prime Impact Acquisition I Shareholders Approve Cheche Deal

Prime Impact Acquisition I in an 8-K said shareholders overwhelmingly approved merging with China-based Cheche Technology, an auto insurance technology platform. The vote was 10,367,834 in favor with 396,621 opposed.

The SPAC’s completion deadline is tomorrow.

The SPAC earlier this week disclosed a PIPE agreement for 1.3 million shares at $10 each to support the deal.

As of March 1, following an extension vote, the SPAC said 2,725,066 shares were presented for redemption, erasing about 41% of the remaining cash held in trust as of the Cheche deal announcement in January. That left the SPAC with about $48 million in trust.

At an enterprise value of $841 million, the deal was originally expected to bring Cheche about $68 million in gross proceeds. Read more.

Total
0
Shares
Related Posts
Read More

HDL Therapeutics Combining with Swiftmerge Acquisition in $480M Deal

The target is a commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia. Cholesterol and calcium deposits are the common culprits behind this arterial condition.